A blood-based biomarker assay is being reported for the early detection and staging of Alzheimer's disease, with potential applicability across ethnic groups. Some outlets are highlighting specific platforms or tests, such as the CircPATH platform or the p-Tau217 test, that have shown promising performance in early detection. However, the relevance of other reports on multi-cancer detection and liquid biopsies to the Alzheimer's disease biomarker assay is unclear.